Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

Nino Keshelava, Peter J. Houghton, Christopher L. Morton, Richard B. Lock, Hernan Carol, Stephen T. Keir, John M. Maris, C. Patrick Reynolds, Richard Gorlick, E. Anders Kolb, Jianrong Wu, Malcolm A. Smith

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.

Original languageEnglish (US)
Pages (from-to)505-508
Number of pages4
JournalPediatric Blood and Cancer
Volume53
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Pediatrics
Heterografts
Neoplasms
Histone Deacetylase Inhibitors
Drug Combinations
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
vorinostat
Growth
In Vitro Techniques
Direction compound

Keywords

  • Developmental therapeutics
  • Preclinical testing
  • Vorinostat

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Keshelava, N., Houghton, P. J., Morton, C. L., Lock, R. B., Carol, H., Keir, S. T., ... Smith, M. A. (2009). Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 53(3), 505-508. https://doi.org/10.1002/pbc.21988

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. / Keshelava, Nino; Houghton, Peter J.; Morton, Christopher L.; Lock, Richard B.; Carol, Hernan; Keir, Stephen T.; Maris, John M.; Reynolds, C. Patrick; Gorlick, Richard; Kolb, E. Anders; Wu, Jianrong; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 53, No. 3, 09.2009, p. 505-508.

Research output: Contribution to journalArticle

Keshelava, N, Houghton, PJ, Morton, CL, Lock, RB, Carol, H, Keir, ST, Maris, JM, Reynolds, CP, Gorlick, R, Kolb, EA, Wu, J & Smith, MA 2009, 'Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 53, no. 3, pp. 505-508. https://doi.org/10.1002/pbc.21988
Keshelava, Nino ; Houghton, Peter J. ; Morton, Christopher L. ; Lock, Richard B. ; Carol, Hernan ; Keir, Stephen T. ; Maris, John M. ; Reynolds, C. Patrick ; Gorlick, Richard ; Kolb, E. Anders ; Wu, Jianrong ; Smith, Malcolm A. / Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2009 ; Vol. 53, No. 3. pp. 505-508.
@article{a2663d8f7587490faa5ff54f7e9d5aee,
title = "Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program",
abstract = "Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.",
keywords = "Developmental therapeutics, Preclinical testing, Vorinostat",
author = "Nino Keshelava and Houghton, {Peter J.} and Morton, {Christopher L.} and Lock, {Richard B.} and Hernan Carol and Keir, {Stephen T.} and Maris, {John M.} and Reynolds, {C. Patrick} and Richard Gorlick and Kolb, {E. Anders} and Jianrong Wu and Smith, {Malcolm A.}",
year = "2009",
month = "9",
doi = "10.1002/pbc.21988",
language = "English (US)",
volume = "53",
pages = "505--508",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

AU - Keshelava, Nino

AU - Houghton, Peter J.

AU - Morton, Christopher L.

AU - Lock, Richard B.

AU - Carol, Hernan

AU - Keir, Stephen T.

AU - Maris, John M.

AU - Reynolds, C. Patrick

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Wu, Jianrong

AU - Smith, Malcolm A.

PY - 2009/9

Y1 - 2009/9

N2 - Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.

AB - Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.

KW - Developmental therapeutics

KW - Preclinical testing

KW - Vorinostat

UR - http://www.scopus.com/inward/record.url?scp=67651205908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651205908&partnerID=8YFLogxK

U2 - 10.1002/pbc.21988

DO - 10.1002/pbc.21988

M3 - Article

C2 - 19418547

AN - SCOPUS:67651205908

VL - 53

SP - 505

EP - 508

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -